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ABSTRACT
INTRODUCTION: In the UK, about 30% of children under 3 years of age visit their GP each year with acute otitis media (AOM), and 97%
of these receive antibiotics. In the US, AOM is the most common reason for outpatient antibiotic treatment.Without antibiotics, AOM resolves
within 24 hours in about 60% of children, and within 3 days in about 80% of children. METHODS AND OUTCOMES: We conducted a sys-
tematic review and aimed to answer the following clinical questions: What are the effects of treatments for AOM in children; and what are
the effects of interventions to prevent recurrence? We searched: Medline, Embase, The Cochrane Library, and other important databases
up to September 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this
review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines
and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 29 systematic reviews, RCTs, or observational studies that
met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this system-
atic review we present information relating to the effectiveness and safety of the following interventions: analgesics, antibiotics, delayed
antibiotics, immediate antibiotics, long-term antibiotic prophylaxis, longer courses of antibiotics, myringotomy, pneumococcal vaccination,
tympanostomy with ventilation tubes, xylitol syrup or gum, and influenza vaccination.
QUESTIONS
What are the effects of treatments for AOM in children?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
What are the effects of interventions to prevent recurrence of AOM in children?. . . . . . . . . . . . . . . . . . . . . . . . 18
INTERVENTIONS
TREATMENTS FOR AOM IN CHILDREN
 Likely to be beneficial
Analgesics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Trade off between benefits and harms
Antibiotics (reduce symptoms more quickly than placebo
but increase adverse effects) . . . . . . . . . . . . . . . . . . 6
Choice of antibiotic regimen . . . . . . . . . . . . . . . . . . . 9
Immediate compared with delayed antibiotic treatment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Longer courses of antibiotics (reduce treatment failure
in the short term but not the long term) . . . . . . . . . 13
 Likely to be ineffective or harmful
Myringotomy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
PREVENTING RECURRENCE OF AOM IN CHILDREN
 Likely to be beneficial
Pneumococcal vaccine . . . . . . . . . . . . . . . . . . . . . . 19
Trade off between benefits and harms
Antibiotic prophylaxis (long term) . . . . . . . . . . . . . 18
 Unlikely to be beneficial
Influenza vaccine  New . . . . . . . . . . . . . . . . . . . . . 23
Xylitol syrup or gum  New . . . . . . . . . . . . . . . . . . . . 24
 Likely to be ineffective or harmful
Tympanostomy (ventilation tubes) . . . . . . . . . . . . . 21
Covered elsewhere in Clinical Evidence
See chronic suppurative otitis media
See otitis media with effusion
Key points
• AOM is characterised by sudden onset of earache with a cloudy or bulging erythematous eardrum caused by
middle-ear infection.
Middle-ear effusion without signs of infection lasting >3 months suggests otitis media with effusion ('glue ear'),
while chronic suppurative otitis media is characterised by continuing middle-ear inflammation and discharge
through a perforated eardrum. These disorders are assessed in separate reviews in Clinical Evidence.
The most common pathogens in AOM in the US and UK are Streptococcus pneumoniae, Haemophilus influenzae,
and Moraxella catarrhalis.
In the UK, about 30% of children under 3 years of age visit their GP each year with AOM, and 97% of these receive
antibiotics. In the US, AOM is the most common reason for outpatient antibiotic treatment.
• Without antibiotics, AOM resolves within 24 hours in about 60% of children, and within 3 days in about 80% of
children.
Analgesics and topical anaesthetics may reduce earache.
Child health
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Antibiotics seem to reduce pain at 2 to 7 days, but they increase the risks of vomiting, diarrhoea, and rashes
compared with placebo.
Immediate antibiotic use seems most beneficial in children aged <2 years with bilateral AOM and in children with
AOM presenting with otorrhoea.
We do not know whether any one antibiotic regimen should be used in preference to another, although amoxicillin
may be more effective than macrolides, and it should be considered as first-line treatment.
Longer courses of antibiotics reduce short-term treatment failure but have no benefit in the longer term compared
with shorter regimens.
Immediate use of antibiotics may provide short-term reduction in some symptoms of AOM, but it increases the
risk of diarrhoea and rashes compared with delayed treatment.
• Myringotomy seems less effective than antibiotics at reducing symptoms.
• We found limited evidence of only a short-term benefit from tympanostomy with ventilation tubes, with possibly in-
creased risks of tympanosclerosis.
• Long-term antibiotic prophylaxis may reduce recurrence rates; however, the possibility of adverse effects and an-
tibiotic resistance should be taken into account.
We do not know whether any one regimen should be used in preference to another to prevent recurrent attacks.
• Vaccination in infancy with pneumococcal conjugate vaccine (PCV) has some effect on recurrent AOM.
Vaccination with PCV in children aged 1 to 7 years does not reduce AOM recurrence.
• Influenza vaccine in healthy children has no effect on incidence of AOM.
• Xylitol given 5 times daily as prophylaxis has a small preventive effect on recurrent AOM, but the compliance issues
in giving a medicine 5 times daily to such young children render it an unrealistic treatment option.
DEFINITION Otitis media is an inflammation in the middle ear. Subcategories include acute otitis media (AOM),
recurrent AOM, and chronic suppurative otitis media (CSOM). AOM is the presence of middle-ear
effusion in conjunction with rapid onset of one or more signs or symptoms of inflammation of the
middle ear. AOM presents with systemic and local signs, and it has a rapid onset. The diagnosis
is made on the basis of signs and symptoms, principally earache in the presence of a cloudy or
bulging eardrum (and immobility of the eardrum if pneumatic otoscopy is performed). Erythema is
a moderately useful sign for helping to establish the diagnosis. If the eardrum has a normal colour,
then risk of AOM is low. [1]  Uncomplicated AOM is limited to the middle-ear cleft. [2] The persistence
of an effusion beyond 3 months without signs of infection defines otitis media with effusion (also
known as 'glue ear'; see review on otitis media with effusion), which can arise as a consequence
of AOM, but can also occur independently. CSOM is characterised by continuing inflammation in
the middle ear causing discharge (otorrhoea) through a perforated tympanic membrane (see review
on CSOM). This review deals only with AOM in children.
INCIDENCE/
PREVALENCE
AOM is common, and has a high morbidity and low mortality in otherwise healthy children. In the
UK, about 30% of children under 3 years visit their general practitioner with AOM each year, and
97% receive antimicrobial treatment. [3]  By 3 months of age, 10% of children have had an episode
of AOM. It is the most common reason for outpatient antimicrobial treatment in the US. [4]
AETIOLOGY/
RISK FACTORS
The most common bacterial causes of AOM in the US and UK are Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis. [3]  Similar pathogens are found in Colombia.
[5] There is some evidence that the predominant causative pathogen in recurrent AOM is changing
from Streptococcus pneumoniae to Haemophilus influenzae after the release and widespread use
of pneumococcal conjugate vaccine. [6] The established modifiable risk factors for recurrent AOM
are the use of pacifiers, and care in daycare centres. Probable risk factors are privation of mother's
milk, presence of siblings, craniofacial abnormalities, passive smoking, and presence of adenoids.
[7]
PROGNOSIS Without antibiotic treatment, AOM symptoms improve in 24 hours in about 60% of children, and in
about 80% of children the condition resolves in about 3 days. Suppurative complications occur in
about 0.12% of children if antibiotics are withheld. [8]  Serious complications are rare in otherwise
healthy children but include hearing loss, mastoiditis, meningitis, and recurrent attacks. [3] The
WHO estimates that, in developing countries, 51,000 children aged <5 years die from complications
of otitis media each year. [9]
AIMS OF
INTERVENTION
To reduce the severity and duration of pain and other symptoms; to prevent complications; to
minimise adverse effects of treatment.
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OUTCOMES Symptoms of AOM (including pain [which can be assessed by surrogate measures such as
parental observation of distress/crying and analgesic use], fever, middle-ear effusion, and otoscopic
appearance); recurrence of infection, mastoiditis, and meningitis; complications of infection
(including deafness), adverse effects of treatment.
METHODS Clinical Evidence search and appraisal September 2010. The following databases were used to
identify studies for this systematic review: Medline 1966 to September 2010, Embase 1980 to
September 2010, and The Cochrane Database of Systematic Reviews, August 2010 (online; 1966
to date of issue). This review was edited using The Cochrane Database of Systematic Reviews
2010, Issue 4. An additional search within The Cochrane Library was carried out for the Database
of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA). We also
searched for retractions of studies included in the review. Abstracts of the studies retrieved from
the initial search were assessed by an information specialist. Selected studies were then sent to
the contributor for additional assessment, using predetermined criteria to identify relevant studies.
Study design criteria for inclusion in this review were: published systematic reviews of RCTs and
RCTs in any language, at least single blinded, and containing >20 individuals of whom >80% were
followed up. There was no minimum length of follow-up required to include studies. We excluded
all studies described as "open", "open label", or not blinded unless blinding was impossible. We
included systematic reviews of RCTs and RCTs where harms of an included intervention were
studied applying the same study design criteria for inclusion as we did for benefits. In addition we
use a regular surveillance protocol to capture harms alerts from organisations such as the FDA
and the MHRA, which are added to the reviews as required. To aid readability of the numerical
data in our reviews, we round many percentages to the nearest whole number. Readers should
be aware of this when relating percentages to summary statistics such as relative risks (RRs) and
odds ratios (ORs). We have performed a GRADE evaluation of the quality of evidence for interven-
tions included in this review (see table, p 29 ). The categorisation of the quality of the evidence
(high, moderate, low, or very low) reflects the quality of evidence available for our chosen outcomes
in our defined populations of interest. These categorisations are not necessarily a reflection of the
overall methodological quality of any individual study, because the Clinical Evidence population
and outcome of choice may represent only a small subset of the total outcomes reported, and
population included, in any individual trial. For further details of how we perform the GRADE eval-
uation and the scoring system we use, please see our website (www.clinicalevidence.com).
QUESTION What are the effects of treatments for AOM in children?
OPTION ANALGESICS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Analgesics and topical anaesthetics may reduce earache compared with placebo.
• Note:
A drug safety alert has been issued by the Food Drug Administration (FDA) on the risk of rare but serious skin
reactions with paracetamol (acetaminophen).
Benefits and harms
Topical anaesthetic versus placebo:
We found one systematic review (search date 2009, 2 RCTs). [10]
-
Symptoms of AOM
Compared with placebo Topical anaesthetic drops may be more effective at reducing earache 10 to 30 minutes after
administration in children taking paracetamol (low-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Pain
topical anaesthetic
drops
RR 1.51
95% CI 1.06 to 2.15
25% reduction in ear ache , 10
minutes
37/58 (64%) with topical anaes-
thetic drops
117 people aged 3
to 19 years
2 RCTs in this
analysis
[10]
Systematic
review P = 0.02
NNT 425/59 (42%) with placebo
95% CI 3 to 27
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
All participants also received
paracetamol. See further informa-
tion on studies for full details of
co-interventions
topical anaesthetic
drops
RR 1.34
95% CI 1.04 to 1.71
25% reduction in ear ache , 20
minutes
46/58 (79%) with topical anaes-
thetic drops
117 people aged 3
to 19 years
2 RCTs in this
analysis
[10]
Systematic
review P = 0.02
NNT 535/59 (59%) with placebo
95% CI 3 to 27All participants also received
paracetamol. See further informa-
tion on studies for full details of
co-interventions
topical anaesthetic
drops
RR 1.34
95% CI 1.12 to 1.61
25% reduction in ear ache , 30
minutes
54/58 (93%) with topical anaes-
thetic drops
117 people aged 3
to 19 years
2 RCTs in this
analysis
[10]
Systematic
review P <0.002
NNT 541/59 (69%) with placebo
95% CI 3 to 10All participants also received
paracetamol. See further informa-
tion on studies for full details of
co-interventions
topical anaesthetic
drops
RR 2.13
95% CI 1.19 to 3.80
50% reduction in ear ache , 10
minutes
25/58 (43%) with topical anaes-
thetic drops
117 people aged 3
to 19 years
2 RCTs in this
analysis
[10]
Systematic
review P = 0.01
NNT 412/59 (20%) with placebo
95% CI 3 to 16All participants also received
paracetamol. See further informa-
tion on studies for full details of
co-interventions
Not significant
RR 1.24
95% CI 0.88 to 1.74
50% reduction in ear ache , 20
minutes
34/58 (59%) with topical anaes-
thetic drops
117 people aged 3
to 19 years
2 RCTs in this
analysis
[10]
Systematic
review P = 0.22
28/59 (47%) with placebo
All participants also received
paracetamol. See further informa-
tion on studies for full details of
co-interventions
topical anaesthetic
drops
RR 1.43
95% CI 1.12 to 1.81
50% reduction in ear ache , 30
minutes
49/58 (84%) with topical anaes-
thetic drops
117 people aged 3
to 19 years
2 RCTs in this
analysis
[10]
Systematic
review P = 0.003
NNT 435/59 (59%) with placebo
95% CI 3 to 11All participants also received
paracetamol. See further informa-
tion on studies for full details of
co-interventions
-
Recurrence
-
-
No data from the following reference on this outcome. [10]
-
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Complications
-
-
No data from the following reference on this outcome. [10]
-
Adverse effects
-
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Adverse effects
One RCT in the review reported
on adverse effects. The review
reported that 3 people (treatment
Adverse effects
with topical anaesthetic drops
63 people aged 3
to 19 years
Data from 1 RCT
[10]
Systematic
review arm not specified) had mild dizzi-
ness that required no further
treatment
with placebo
All participants also received
paracetamol. See further informa-
tion on studies for full details of
co-interventions
-
-
Oral analgesics versus placebo:
We found one RCT comparing the effects of treatment with ibuprofen or paracetamol three times daily versus
placebo for 48 hours. [11]
-
Symptoms of AOM
Compared with placebo Oral ibuprofen or paracetamol may be more effective at reducing pain after 48 hours in
children taking antibiotics (low-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Pain
ibuprofen
P <0.01Incidence of ear ache , 2 days
5/71 (7%) with ibuprofen
219 children, aged
1 to 6 years with
otoscopically diag-
nosed AOM and
[11]
RCT
19/75 (25%) with placebo
receiving antibiotic
Parent assessed outcometreatment with cefa-
clor for 7 days
Not significant
P value not reported
Reported as non-significant
Incidence of ear ache , 2 days
7/73 (10%) with paracetamol
219 children, aged
1 to 6 years with
otoscopically diag-
nosed AOM and
[11]
RCT
19/75 (25%) with placebo
receiving antibiotic
Parent assessed outcometreatment with cefa-
clor for 7 days
-
Recurrence
-
-
No data from the following reference on this outcome. [11]
-
Complications
-
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-No data from the following reference on this outcome. [11]
-
Adverse effects
-
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Adverse effects
Significance not assessedAdverse effects (including mild
nausea, vomiting, or abdominal
pain)
219 children, aged
1 to 6 years with
otoscopically diag-
nosed AOM and
[11]
RCT
5/71 (7%) with ibuprofenreceiving antibiotic
treatment with cefa-
clor for 7 days
3/75 (4%) with placebo
Significance not assessedAdverse effects (including mild
nausea, vomiting, or abdominal
pain)
219 children, aged
1 to 6 years with
otoscopically diag-
nosed AOM and
[11]
RCT
3/73 (4.1%) with paracetamolreceiving antibiotic
treatment with cefa-
clor for 7 days
3/75 (4.0%) with placebo
-
-
-
Further information on studies
[11] The evidence from this RCT is limited because the assessment of the child's pain relief was based on parental
observation using a scale of 0 or 1.
[10] The review included studies in which participants were also given oral analgesics. It is therefore difficult to
properly assess the real effects of the anaesthetic ear drops.
-
-
Comment: None.
OPTION ANTIBIOTICS VERSUS PLACEBO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Antibiotics may lead to more rapid reduction in symptoms of AOM, but they increase the risk of adverse effects.
• Antibiotics seem to reduce pain at 2 to 7 days, but they increase the risks of vomiting, diarrhoea, and rashes
compared with placebo.
• Antibiotics seem most effective in children aged <2 years with bilateral AOM and in children with AOM presenting
with otorrhoea.
Benefits and harms
Antibiotics versus placebo:
We found 4 systematic reviews (search dates 1997, [12]  2008, [13]  and 2005 [14] [15] ).
-
Symptoms of AOM
Compared with placebo Antibiotics may be more effective at reducing pain and other symptoms of AOM after 2 to
14 days (low-quality evidence).
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Symptoms of AOM
Not significant
OR 1.31 (weighted OR, Man-
tel–Haenszel)
Symptomatic improvement , 7
days
741 children aged
<2 years
[12]
Systematic
review 95% CI 0.83 to 2.08357/416 (86%) with antibiotics4 RCTs in this
analysis 277/325 (85%) with placebo
alone or versus placebo plus
myringotomy
Antibiotic treatment included
penicillins, sulphonamide, amoxi-
cillin–clavulanic acid (co-amoxi-
clav)
See further information on studies
for definitions of AOM in trials
antibiotics
ARR 6%
95% CI 4% to 9%
Pain , 2 to 7 days
228/1425 (16%) with ery-
thromycin, penicillins,
sulphonamides
2791 children aged
6 months to 15
years
9 RCTs in this
analysis
[13]
Systematic
review RR 0.72
95% CI 0.19 to 0.40303/1366 (22%) with placebo
P <0.001Pain was assessed using
parental report/score card/diary
or clinician assessment at 4 days
NNT 16
95% CI 11 to 25
Not significant
RR 0.90
95% CI 0.78 to 1.04
Pain outcomes , 24 hours
223/624 (36%) with antibiotics
1229 children aged
6 months to 15
years
[13]
Systematic
review 241/605 (40%) with placebo4 RCTs in this
analysis
antibiotics
RR 0.64
95% CI 0.62 to 0.80
Pain, fever, or both , 3 to 7
days
42/140 (30%) with antibiotics
273 children <2
years with bilateral
AOM
6 RCTs in this
analysis
[15]
Systematic
review The differences for children aged
<2 years with unilateral AOM and
in children >2 years with unilater-
74/133 (55%) with placebo
Subgroup analysis al or bilateral AOM were not sig-
nificant
antibiotics
RR 0.52
95% CI 0.37 to 0.73
Pain, fever, or both , 3 to 7
days
12/50 (24%) with antibiotics
116 children aged
6 months to 12
years presenting
with otorrhoea
[15]
Systematic
review P = 0.04
39/66 (60%) with placebo6 RCTs in this
analysis
Subgroup analysis
-
No data from the following reference on this outcome. [14]
-
Recurrence
Compared with placebo Antibiotics are no more effective at reducing the rate of recurrence in children with AOM
(high-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Recurrence
Not significant
RR 0.93
95% CI 0.79 to 1.10
Recurrence
214/1113 (19%) with penicillins
2153 people aged
6 months to 15
years
[13]
Systematic
review 214/1040 (21%) with placebo6 RCTs in this
analysis
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-No data from the following reference on this outcome. [12] [14] [15]
-
Complications
Compared with placebo Antibiotics seem no more effective at reducing the risk of abnormal tympanometry at 1 and
3 months in children with AOM (moderate-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Abnormal tympanometry
Not significant
RR 0.97
95% CI 0.76 to 1.24
Abnormal tympanometry , 3
months
96/410 (23%) with antibiotics
808 children aged
6 months to 10
years
3 RCTs in this
analysis
[13]
Systematic
review P = 0.81
96/460 (24%) with placebo
Not significant
RR 0.89
95% CI 0.75 to 1.07
Abnormal tympanometry , 1
month
153/467 (33%) with antibiotics
927 children aged
6 months to 12
years
4 RCTs in this
analysis
[13]
Systematic
review P = 0.21
168/460 (37%) with placebo
Not significant
RR 0.93
95% CI 0.82 to 1.04
Abnormal tympanometry , 1
month
47% with antibiotics
1328 children aged
6 months to 12
years
5 RCTs in this
analysis
[14]
Systematic
review
51% with placebo or no treatment
Absolute numbers not reported
-
No data from the following reference on this outcome. [12] [15]
-
Adverse effects
-
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Adverse effects
placebo
RR 1.38
95% CI 1.09 to 1.76
Adverse effects, including
vomiting, diarrhoea, or rashes
110/690 (16%) with antibiotics
1401 children,
aged 6 months to
15 years
5 RCTs in this
analysis
[13]
Systematic
review P = 0.008
NNH 2483/711 (11%) with placebo
95% CI 9 to 152
-
No data from the following reference on this outcome. [12] [14] [15]
-
-
-
Further information on studies
[12] Three RCTs based diagnosis of AOM on otoscopic appearance of the tympanic membrane and clinical signs
of acute infection, and one RCT based diagnosis on otoscopy findings alone.
-
-
Comment: None.
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Clinical guide:
The results of systematic reviews comparing antibiotics versus placebo may vary owing to differences
in entry criteria and outcome measures. One quasi-randomised trial from Sweden conducted in
1954 comparing the effects of antibiotics versus placebo found no cases of mastoiditis in the
penicillin-treated group, whereas 17% of the control group developed mastoiditis. [16] Therefore,
in populations in which the incidence of complicating mastoiditis is high, antibiotic treatment would
be advised.
OPTION CHOICE OF ANTIBIOTIC REGIMEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• We do not know whether any one antibiotic regimen should be used in preference to another, but amoxicillin
may be more effective than macrolides, and it should be considered as first-line treatment.
• Note
Antibiotics increase the risk of vomiting, diarrhoea, and rashes compared with placebo, but rates may vary between
different types of antibiotic.
Benefits and harms
Different antibiotics versus each other:
We found three systematic reviews (search dates 1992, [17]  1999, [2]  and 2008 [18] ).
-
Symptoms of AOM
Different antibiotics compared with each other Macrolide antibiotics may be less effective than amoxicillin or amoxi-
cillin–clavulanic acid (co-amoxiclav) at reducing signs and symptoms of AOM after 7 to 14 days, while other antibiotics
may be as effective as each other (very low-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Symptoms of AOM
Not significant
P values not reported
Reported as not significant for all
comparisons
Primary control defined as ab-
sence of any symptom or sign
, 7 to 14 days
with
4580 children aged
4 months to 18
years
27 RCTs in this
analysis
[17]
Systematic
review
with
Absolute numbers not reported
The review reported comparisons
of a range of antibiotics, including
ampicillin, amoxicillin, ceflacor,
cefixime, amoxicillin–clavulanic
acid (co-amoxiclav), ery-
thromycin, penicillin, and sulfafu-
razole
Not significant
Clinical failure rate difference:
+4.5%
Clinical failure rate , 7 to 14
days
491 children, aged
4 weeks to 18
years
[2]
Systematic
review 95% CI –1.8% to +10.7%with penicillin
3 RCTs in this
analysis with ampicillin or amoxicillin
Absolute results not reported
Not significant
Clinical failure rate difference
–5.4%
Clinical failure rates , 3 to 7
days
185 children, aged
4 weeks to 18
years
[2]
Systematic
review 95% CI –15.2% to +4.4%with cefaclor
4 RCTs in this
analysis with ampicillin or amoxicillin
Absolute numbers not reported
amoxicillin or
amoxicillin–clavu-
lanic acid
RR 1.31
95% CI 1.07 to 1.60
P = 0.008
Clinical failure , 10 to 16 days
146/1371 (11%) with amoxicillin
or amoxicillin–clavulanic acid
196/1395 (14%) with macrolide
antibiotics
2766 children aged
6 months to 15
years
10 RCTs in this
analysis
[18]
Systematic
review
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-Recurrence
-
-
No data from the following reference on this outcome. [2] [17] [18]
-
Complications
-
-
No data from the following reference on this outcome. [2] [17] [18]
-
Adverse effects
-
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Adverse effects
amoxicillin or
ampicillin
ARI 8.4%
95% CI 3.8% to 13.1%
Diarrhoea
with cefixime
1518 patients aged
4 weeks to 18
years
[2]
Systematic
review NNH 12with amoxicillin or ampicillin5 RCTs in this
analysis 95% CI 8 to 27Absolute numbers not reported
azithromycin
ARI 18%
95% CI 8% to 28%
Gastrointestinal adverse ef-
fects
with amoxicillin–clavulanic acid
(co-amoxiclav)
1366 patients aged
4 weeks to 18
years
3 RCTs in this
analysis
[2]
Systematic
review NNH 6
95% CI 4 to 13
with azithromycin
Absolute numbers not reported
macrolide antibi-
otics
RR 0.74
95% CI 0.60 to 0.90
Adverse effects
with amoxicillin or amoxi-
cillin–clavulanic acid
2766 children aged
6 months to 15
years
10 RCTs in this
analysis
[18]
Systematic
review P = 0.003
with macrolide antibiotics
Absolute numbers not reported
-
No data from the following reference on this outcome. [17]
-
-
-
Further information on studies
[2] Clinical failure was defined as the presence of pain, fever, middle-ear effusion, clinical signs of otitis media, or
suppurative complications such as mastoiditis.
[17] AOM was defined as bulging or opacification of the tympanic membrane with or without erythema, accompanied
by at least one sign (fever, ear ache, irritability, otorrhoea, lethargy, anorexia, vomiting, diarrhoea, poor or absent
mobility of the tympanic membrane). Treatment success was defined as absence of all presenting signs and
symptoms of AOM at the evaluation point closest to 7 to 14 days after start of treatment.
-
-
Comment: Clinical guide:
Many RCTs have studied a variety of antibiotic regimens for the treatment of otitis media, but there
is heterogeneity in participants, treatment regimens, controls, and outcome measures.
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OPTION IMMEDIATE VERSUS DELAYED ANTIBIOTIC TREATMENT. . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Immediate use of antibiotics may provide short-term reduction for some symptoms of AOM, but it increases the
risk of rashes and diarrhoea compared with delayed treatment.
Benefits and harms
Immediate versus delayed antibiotic treatment:
We found one systematic review (search date 2009). [19]  Owing to heterogeneity among studies, the review did not
perform meta-analyses, so we report data from individual RCTs here.
-
Symptoms of AOM
Immediate antibiotics compared with delayed antibiotics Immediate antibiotics may be more effective at reducing
pain and other symptoms of AOM at 3 days, but not after 7 days (moderate-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Symptoms of AOM
Not significant
OR 1.93
95% CI 0.96 to 3.88
Proportion of children with
pain , 3 days
28/111 (25%) with delayed antibi-
otics
212 children aged
6 months to 10
years
Data from 1 RCT
[19]
Systematic
review
15/101 (15%) with immediate
antibiotics
Not significant
OR 6.55
95% CI 0.33 to 128.34
Proportion of children with
pain , 7 days
3/111 (3%) with delayed antibi-
otics
212 children aged
6 months to 10
years
Data from 1 RCT
[19]
Systematic
review
0/101 (0%) with immediate antibi-
otics
immediate antibi-
otics
OR 2.62
95% CI 1.44 to 4.76
Proportion of children with
malaise , 3 days
45/150 (30%) with delayed antibi-
otics
285 children aged
6 months to 10
years
Data from 1 RCT
[19]
Systematic
review
19/135 (14%) with immediate
antibiotics
immediate antibi-
otics
Mean difference 0.75
95% CI 0.26 to 1.24
Mean pain severity , 3 days
2.56 with delayed antibiotics
213 children aged
6 months to 10
years
[19]
Systematic
review 1.81 with immediate antibioticsData from 1 RCT
Not significant
Mean difference +0.12
95% CI –0.04 to +0.28
Mean pain severity , 7 days
1.17 with delayed antibiotics
212 children aged
6 months to 10
years
[19]
Systematic
review 1.05 with immediate antibioticsData from 1 RCT
immediate antibi-
otics
Mean difference 0.59
95% CI 0.25 to 0.93
Mean number of spoons of
paracetamol/day
2.28 with delayed antibiotics
282 children aged
6 months to 12
years
Data from 1 RCT
[19]
Systematic
review
1.69 with immediate antibiotics
Not significant
OR 0.88
95% CI 0.53 to 1.47
Fever , days 4 to 6
42/132 (32%) with delayed antibi-
otics
265 children aged
6 months to 12
years
Data from 1 RCT
[19]
Systematic
review
46/133 (35%) with immediate
antibiotics
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Not significant
OR 0.89
95% CI 0.54 to 1.48
Proportion of children with
pain , days 4 to 6
85/132 (64%) with delayed antibi-
otics
265 children aged
6 months to 12
years
Data from 1 RCT
[19]
Systematic
review
89/133 (67%) with immediate
antibiotics
Not significant
OR 1.48
95% CI 0.61 to 3.59
Use of paracetamol or ibupro-
fen
123/132 (93%) with delayed an-
tibiotics
265 children aged
6 months to 12
years
Data from 1 RCT
[19]
Systematic
review
120/133 (90%) with immediate
antibiotics
Not significant
OR 1.21
95% CI 0.52 to 2.81
Re-consultation rate
13/132 (10%) with delayed antibi-
otics
265 children aged
6 months to 12
years
Data from 1 RCT
[19]
Systematic
review
11/133 (8%) with immediate an-
tibiotics
-
Recurrence
-
-
No data from the following reference on this outcome. [19]
-
Complications
-
-
No data from the following reference on this outcome. [19]
-
Adverse effects
-
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Adverse effects
Not significant
OR 1.21
95% CI 0.41 to 2.58
Rash
8/150 (5%) with delayed antibi-
otics
285 children aged
between 6 months
and 12 years
Data from 1 RCT
[19]
Systematic
review
14/150 (9%) with immediate an-
tibiotics
delayed antibiotics
OR 0.27
95% CI 0.13 to 0.58
Diarrhoea
10/132 (8%) with delayed antibi-
otics
265 children aged
between 6 months
and 12 years
Data from 1 RCT
[19]
Systematic
review
31/133 (23%) with immediate
antibiotics
Not significant
OR 1.01
95% CI 0.47 to 2.16
Vomiting
15/132 (11.4%) with delayed an-
tibiotics
265 children aged
between 6 months
and 12 years
Data from 1 RCT
[19]
Systematic
review
15/133 (11.3%) with immediate
antibiotics
-
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Further information on studies
-
-
Comment: Prescribing delayed antibiotics, using a prescription to be filled later if symptoms do not improve,
is a tool for the physician to reduce antibiotic use rather than a treatment option for AOM. If antibiotics
have a small effect on the outcome of AOM, then this effect will clearly apply to immediate antibiotics.
Because the evidence suggests that antibiotics should only be prescribed to certain subgroups of
patients (children aged <2 years with bilateral AOM and children with AOM presenting with otor-
rhoea), physicians should discuss the wait-and-see policy with parents of children not in those
subgroups. A delayed prescription should be provided with care, since oral antibiotics may not always
be the best option in very young children with worsening symptoms. In these cases the physician
and not the parents of the child should make the decision about whether to give antibiotics. In most
developed countries, it is relatively easy for parents to re-consult a physician when symptoms either
do not improve or get worse.
One study in the review showed no difference in re-consultation rate between the two groups. [19]
One study comparing delayed antibiotics versus no antibiotics showed no difference in the outcomes
of pain and fever. [20]
OPTION LONGER VERSUS SHORTER COURSES OF ANTIBIOTICS. . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Longer courses of antibiotics reduce short-term treatment failure, but have no benefit over the longer term com-
pared with shorter regimens.
Benefits and harms
Longer versus shorter course of antibiotics:
We found one systematic review (search date 2009). [21]
-
Symptoms of AOM
Longer courses of antibiotics compared with shorter courses Longer (8–10 days) courses of antibiotics are more
effective at reducing symptoms and preventing relapse or re-infection at 8 to 19 days compared with 7-day courses,
but are no more effective than shorter courses after 20 to 30 days (high-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Symptoms of AOM
longer-course an-
tibiotics
OR 1.34
95% CI 1.15 to 1.55
Treatment failure , 1 month or
less
486/2376 (20%) with short-course
antibiotics (<7 days)
5093 children aged
between 4 weeks
and 15 years
16 RCTs in this
analysis
[21]
Systematic
review P = 0.0001
475/2717 (17%) with longer-
course antibiotics (8–10 days)
See further information on studies
for definition of treatment failure
longer-course an-
tibiotics
OR 1.37
95% CI 1.15 to 1.64
Treatment failure , 8 to 19 days
340/1892 (18%) with short-course
antibiotics (<7 days)
3932 children aged
between 4 weeks
and 15 years
11 RCTs in this
analysis
[21]
Systematic
review P = 0.0004
293/2040 (14%) with longer-
course antibiotics (8–10 days)
See further information on studies
for definition of treatment failure
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Not significant
OR 1.16
95% CI 0.94 to 1.42
Treatment failure , 20 to 30
days
238/1141 (21%) with short-course
antibiotics (<7 days)
2475 children aged
between 4 weeks
and 15 years
9 RCTs in this
analysis
[21]
Systematic
review
271/1335 (20%) with longer-
course antibiotics (8–10 days)
See further information on studies
for definition of treatment failure
Not significant
OR 1.18
95% CI 0.98 to 1.41
Treatment failure , 3 months or
less
391/973 (40%) with short-course
antibiotics (<7 days)
2068 children aged
between 4 weeks
and 15 years
7 RCTs in this
analysis
[21]
Systematic
review
399/1095 (36%) with longer-
course antibiotics (8–10 days)
See further information on studies
for definition of treatment failure
Not significant
OR 1.09
95% CI 0.76 to 1.57
Treatment failure , 1 month or
less
99/296 (33%) with short-course
antibiotics (<7 days)
570 children aged
between 4 weeks
and 2 years
5 RCTs in this
analysis
[21]
Systematic
review
85/274 (31%) with longer-course
antibiotics (8–10 days)
See further information on studies
for definition of treatment failure
Not significant
OR 0.85
95% CI 0.60 to 1.21
Treatment failure , 1 month or
less
74/530 (14%) with short-course
antibiotics (<7 days)
1064 children aged
between 2 years
and 15 years
6 RCTs in this
analysis
[21]
Systematic
review
86/534 (16%) with longer-course
antibiotics (8–10 days)
See further information on studies
for definition of treatment failure
-
Recurrence
-
-
No data from the following reference on this outcome. [21]
-
Complications
-
-
No data from the following reference on this outcome. [21]
-
Adverse effects
-
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Gastrointestinal adverse effects
short-course antibi-
otics (<7 days)
OR 0.72
95% CI 0.60 to 0.87
Gastrointestinal adverse ef-
fects
206/2221 (9%) with short-course
antibiotics (<7 days)
4918 children aged
between 4 weeks
years and 15 years
13 RCTs in this
analysis
[21]
Systematic
review
369/2697 (14%) with longer-
course antibiotics (8–10 days)
-
-
-
Further information on studies
[21] Treatment failure was defined as lack of clinical resolution, relapse, or recurrence of AOM during a 1-month
period following the initiation of therapy. Clinical resolution was defined as improved or resolving signs or
symptoms of AOM. Treatment failure at 3 months was defined as relapses and recurrences up to 3 months.
-
-
Comment: A subgroup analysis showed that children aged <2 years had no benefit from longer courses of
antibiotics compared with shorter courses. In addition, they had a greater risk of treatment failure
compared with older children irrespective of treatment duration. [21]
OPTION MYRINGOTOMY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Myringotomy seems less effective than antibiotics at reducing symptoms.
• Adverse effects
Myringotomy may be less likely than antibiotics to cause diarrhoea.
Benefits and harms
Myringotomy versus no myringotomy:
We found one RCT. [22]
-
Symptoms of AOM
Compared with no myringotomy Myringotomy may be no more effective than no myringotomy at reducing the
symptoms of AOM after 1 to 7 days (low-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Symptoms of AOM
Not significant
P value not reported
Reported as not significant for
myringotomy v no treatment
Pain , 24 hours
26/36 (72.2%) with myringotomy
only
171 children, aged
2 to 12 years with
AOM
The third arm eval-
uated amoxicillin
[22]
RCT
4-armed
trial 29/40 (72.5%) with no treatment
(250 mg three
times daily for 7
days) only
The fourth arm
evaluated amoxi-
cillin plus myringo-
tomy
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Not significant
P value not reported
Reported as not significant for
myringotomy v no treatment
Pain , 7 days
31/35 (89%) with myringotomy
only
171 children, aged
2 to 12 years with
AOM
The third arm eval-
uated amoxicillin
[22]
RCT
4-armed
trial 34/38 (90%) with no treatment
(250 mg three
times daily for 7
days) only
The fourth arm
evaluated amoxi-
cillin plus myringo-
tomy
-
Recurrence
-
-
No data from the following reference on this outcome. [22]
-
Complications
-
-
No data from the following reference on this outcome. [22]
-
Adverse effects
-
-
No data from the following reference on this outcome. [22]
-
-
Myringotomy versus antibiotics:
We found no systematic review but found three RCTs. [23] [22] [24]
-
Symptoms of AOM
Compared with antibiotics Myringotomy may be less effective at reducing symptoms of AOM after 12 hours to 11
days (low-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Symptoms of AOM
antibiotic
P <0.001Persistent ear infection , 9 to
11 days
105 infants aged 3
months to 1 year
with AOM
[23]
RCT
3-armed
trial
21/30 (70%) with myringotomy
plus placebo
2/30 (7%) with antibiotic (amoxi-
cillin–clavulanic acid)
The remaining arm
evaluated myringo-
tomy plus antibiotic
(amoxicillin–clavu-
lanic acid [co-
amoxiclav])
60 children in this analysis
antibiotic
P <0.0001Persistent ear infection , 3 to 6
days
105 infants aged 3
months to 1 year
with AOM
[23]
RCT
3-armed
trial
28/35 (80%) with myringotomy
plus placebo
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
11/35 (31%) with antibiotic
(amoxicillin–clavulanic acid)
The remaining arm
evaluated myringo-
tomy plus antibiotic 70 children in this analysis(amoxicillin–clavu-
lanic acid)
Not significant
P value not reported
Reported as not significant for
myringotomy v amoxicillin alone
No pain , 24 hours
26/36 (72.2%) with myringotomy
34/47 (72.3%) with amoxicillin
(250 mg three times daily for 7
days)
171 children aged
2 to 12 years with
AOM
The remaining
arms evaluated
amoxicillin plus
myringotomy and
no treatment
[22]
RCT
4-armed
trial
83 children in this analysis
Not significant
P value not reported
Reported as not significant
No pain , 7 days
31/35 (89%) with myringotomy
171 children aged
2 to 12 years with
AOM
[22]
RCT
4-armed
trial
43/46 (93%) with amoxicillin
(250 mg three times daily for 7
days)
The remaining
arms evaluated
amoxicillin plus
myringotomy and
no treatment
81 children in this analysis
amoxicillin
P = 0.006
Results include severe episodes
of AOM in children aged 2 to 12
years only
Initial treatment failure , 12
hours
23% with myringotomy plus
placebo
83 episodes of
AOM in children,
aged 2 to 12 years
with severe AOM
or recurrent AOM
[24]
RCT
3-armed
trial
4% with amoxicillin (40 mg/kg/day
in 3 divided doses for 14 days)The remaining armevaluated myringo-
tomy plus amoxi-
cillin
Absolute numbers not reported
-
Recurrence
-
-
No data from the following reference on this outcome. [23] [22] [24]
-
Complications
-
-
No data from the following reference on this outcome. [23] [22] [24]
-
Adverse effects
-
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Adverse effects
myringotomy plus
placebo
P = 0.05Loose or watery bowel move-
ments
105 infants, aged
3 months to 1 year
with AOM
[23]
RCT
3-armed
trial
0/30 (0%) with myringotomy plus
placebo
7/60 (12%) with antibiotic (amox-
icillin–clavulanic acid)
-
No data from the following reference on this outcome. [22] [24]
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-
Further information on studies
[22] The RCT provided results in the form of children or as individual ears as the unit measured. Because randomi-
sation was based on children, the figures reported here exclude those results based on individual ears.
[23] AOM was defined as the presence of middle-ear effusion and bulging (with or without redness of the tympanic
membrane) associated with recent irritability or fever. The RCT provided results in the form of children or as
individual ears as the unit measured. Because randomisation was based on children, the figures reported here
exclude those results based on individual ears.
[24] AOM was diagnosed on the basis of fever, ear ache, or irritability with redness and/or bulging of the eardrum.
An episode of AOM was classified as severe or non-severe according to the child's temperature and an ear
ache score.
-
-
Comment: None.
QUESTION What are the effects of interventions to prevent recurrence of AOM in children?
OPTION ANTIBIOTIC PROPHYLAXIS (LONG TERM). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Long-term antibiotic prophylaxis may reduce recurrence rates; however, the possibility of adverse effects and
antibiotic resistance should be taken into account.
• We do not know whether any one regimen should be used in preference to another to prevent recurrent attacks.
Benefits and harms
Antibiotic prophylaxis versus placebo:
We found one systematic review (13 RCTs, search date 2006), which compared antibiotics versus placebo or no
treatment for the prevention of AOM, AOM with perforation, or chronic suppurative otitis media. [25]
-
Recurrence
Compared with placebo Prophylactic antibiotics are more effective at reducing the incidence of AOM compared with
placebo or no treatment in children at risk of otitis media (high-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Recurrence
antibiotics
RR 0.62
95% CI 0.52 to 0.75
Proportion of children with
AOM or chronic suppurative
otitis media
1358 children at in-
creased risk of
AOM
[25]
Systematic
review
253/748 (34%) with antibiotics13 RCTs in this
analysis 331/610 (54%) with placebo or
no treatment
antibiotics
Incidence rate ratio (IRR) 0.48
95% CI 0.37 to 0.62; see further
information on studies for defini-
tion of IRR
Number of episodes of otitis
media
360 episodes with antibiotics
752 episodes with placebo or no
treatment
1112 children at in-
creased risk of
AOM
12 RCTs in this
analysis
[25]
Systematic
review
Antibiotics prevented 1.5
episodes of AOM for every 12
months of treatment per child
-
Symptoms of AOM
-
© BMJ Publishing Group Ltd 2011. All rights reserved. .......................................................... 18
AOM in children
Child health
-No data from the following reference on this outcome. [25]
-
Complications
-
-
No data from the following reference on this outcome. [25]
-
Adverse effects
-
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Adverse effects
Not significant
RR 1.99
95% CI 0.25 to 15.89
Adverse effects
10/405 (2%) with antibiotics
714 children at in-
creased risk of
AOM
[25]
Systematic
review 3/309 (1%) with placebo or no
treatment11 RCTs in thisanalysis
-
-
-
Further information on studies
[25] The incidence rate ratio (IRR), also known as the rate ratio, is the incidence rate in the intervention group divided
by the incidence rate in the placebo group.
-
-
Comment: Clinical guide:
We found insufficient evidence on which antibiotic to use and for how long, and on how many
episodes of AOM to justify starting preventive treatment.
OPTION PNEUMOCOCCAL VACCINE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Vaccination in infancy with pneumococcal conjugate vaccine (PCV) has some effect on recurrent AOM.
• Vaccination with PCV in children aged 1 to 7 years with recurrent AOM has no effect on recurrences.
• The adverse effects associated with pneumococcal vaccination are unclear.
• Note
We found no clinically important results from RCTs about the effects of the 23-valent pneumococcal vaccine that
is currently available.
Benefits and harms
Pneumococcal vaccine versus placebo or control:
We found one systematic review (search date 2007). [26] The review included 7 RCTs on 7- to 11-valent pneumococcal
conjugate vaccine (PCV) (with different carrier proteins). Owing to significant heterogeneity regarding study population,
type of conjugate vaccine, and outcome measures, the review did not perform a meta-analysis.We therefore present
results from individual RCTs.
-
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Recurrence
Compared with placebo or control vaccine Pneumococcal conjugate vaccine (7- to 11-valent) may be more effective
than placebo at reducing the incidence of AOM when administered during infancy, but may be no more effective
when given to children aged 1 to 7 years with recurrent AOM (very low-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Recurrence
pneumococcal
vaccine
Relative risk reduction (RRR) 6%
95% CI 4% to 8%
Episodes , per person-year
with vaccination
37,868 children
aged 2 months
Data from 1 RCT
[26]
Systematic
review
with control vaccine
Absolute results not reported
Intention-to-treat analysis
Not significant
RRR +6%
95% CI –4% to +16%
Episodes , per person-year
1.16 with vaccination
1662 children aged
2 months
Data from 1 RCT
[26]
Systematic
review 1.24 with control vaccine
Per-protocol analysis
Not significant
RRR –1%
95% CI –12% to +10%
Episodes , per person-year
with vaccination
1666 children aged
2 months
Data from 1 RCT
[26]
Systematic
review
with control vaccine
Absolute results not reported
Per-protocol analysis
pneumococcal
vaccine
RRR 34%
95% CI 21% to 44%
Episodes , per person-year
0.08 with vaccination
4968 children aged
6 weeks to 5
months
[26]
Systematic
review 0.13 with control vaccineData from 1 RCT
Per-protocol analysis
Not significant
RRR +17%
95% CI –2% to +33%
Episodes , per person-year
0.66 with vaccination
264 children aged
12 months to 35
months
[26]
Systematic
review 0.79 with control vaccineData from 1 RCT
Intention-to-treat analysis
control vaccine
RRR –29%
95% CI –62% to –2%
Episodes , per person-year
1.1 with vaccination
383 children aged
1 year to 7 years
with recurrent AOM
[26]
Systematic
review 0.83 with control vaccineData from 1 RCT
Intention-to-treat analysis
Not significant
RRR –16%
95% CI –96% to +31%
Episodes , per person-year
0.78 with vaccination
74 children aged 1
year to 7 years
with recurrent AOM
[26]
Systematic
review 0.67 with control vaccineData from 1 RCT
Per-protocol analysis
pneumococcal
vaccine
RRR 9%
95% CI 4% to 14%
Recurrent AOM
with vaccination
37,868 children
aged 2 months
Data from 1 RCT
[26]
Systematic
review
with control vaccine
Absolute results not reported
Recurrent AOM was defined as
at least 3 episodes in 6 months
or at least 4 episodes in 1 year
Intention-to-treat analysis
Not significant
RRR +9%
95% CI –12% to +27%
Recurrent AOM
with vaccination
1662 children aged
2 months
Data from 1 RCT
[26]
Systematic
review
with control vaccine
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Absolute results not reported
Recurrent AOM was defined as
at least 3 episodes in 6 months
or at least 4 episodes in 1 year
Intention-to-treat analysis
Not significant
RRR +56%
95% CI –2% to +81%
Recurrent AOM
with vaccination
4968 children aged
6 weeks to 5
months
[26]
Systematic
review
with control vaccineData from 1 RCT
Absolute results not reported
Recurrent AOM was defined as
at least 3 episodes in 6 months
or at least 4 episodes in 1 year
Per-protocol analysis
-
Symptoms of AOM
-
-
No data from the following reference on this outcome. [26]
-
Complications
-
-
No data from the following reference on this outcome. [26]
-
Adverse effects
-
-
No data from the following reference on this outcome. [26]
-
-
-
Further information on studies
-
-
Comment: Clinical guide:
Based on the current evidence, the review concluded that pneumococcal conjugate vaccine (PCV)
is marginally beneficial in preventing AOM in infancy. The discrete reductions of 6% may, however,
result in substantial reductions from a public health perspective. In most western countries, PCVs
are implemented in national childhood vaccination programmes because of the effect on invasive
pneumococcal infections. Administering PCVs in older children with a history of AOM has no effect
on preventing further AOM episodes.
OPTION TYMPANOSTOMY (VENTILATION TUBES). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Tympanostomy with ventilation tube insertion leads to short-term reduction in the number of episodes of AOM,
but it increases the risk of complications.
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• We found limited evidence of only a short-term benefit from tympanostomy with ventilation tubes, with possibly
increased risks of tympanosclerosis.
• Tympanostomy plus drainage tubes may increase the risk of tympanosclerosis and hearing impairment.
Benefits and harms
Tympanostomy versus no surgery or myringotomy alone:
We found one systematic review (search date 2008) [27]  and one additional RCT. [28]
-
Recurrence
Compared with no surgery or myringotomy alone Tympanostomy plus insertion of drainage tubes may be more ef-
fective at reducing the incidence of AOM after 6 months, but not after 18 months (very low-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Recurrence
tympanostomy
OR 0.18
95% CI 0.08 to 0.42
Proportion of children with at
least 1 episode of AOM , 6
months
148 children aged
<3 years
2 RCTs in this
analysis
[27]
Systematic
review
40/85 (47%) with tympanostomy
51/63 (81%) with control
tympanostomy
Difference in mean number of
episodes: –1.2
Mean number of episodes of
AOM , 6 months
44 children, aged
9 months to 7
years, with bilateral
[28]
RCT
95% CI –2.2 to –0.90.6% with tympanostomy tube
insertion into a randomly selected
ear
recurrent AOM of
equal severity in
each ear despite
>3 months of antibi-
otic prophylaxis
1.8% with contralateral ear receiv-
ing either no surgery or myringo-
tomy alone
Absolute numbers not reported
Not significant
Difference in mean number of
episodes 0%
Mean number of episodes of
AOM , 18 months
44 children, aged
9 months to 7
years, with bilateral
[28]
RCT
95% CI –0.3 to +0.30.8% with tympanostomy tube
insertion into a randomly selected
ear
recurrent AOM of
equal severity in
each ear despite
>3 months of antibi-
otic prophylaxis
0.8% with contralateral ear receiv-
ing either no surgery or myringo-
tomy alone
Absolute numbers not reported
Not significant
P = 0.3
The RCT reported a non-signifi-
cant trend towards more recur-
Recurrent ear infections
with tympanostomy tube insertion
into a randomly selected ear
44 children, aged
9 months to 7
years, with bilateral
recurrent AOM of
equal severity in
[28]
RCT
rent infections and worse hearing
in ears that had received tympa-with contralateral ear receiving
either no surgery or myringotomy
alone
each ear despite
>3 months of antibi-
otic prophylaxis
nostomy tubes, which became
apparent after tube extrusion
Absolute results not reported
-
Complications
Compared with no surgery or myringotomy alone Tympanostomy plus insertion of drainage tubes may increase the
risk of tympanosclerosis in children with AOM (low-quality evidence).
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Tympanosclerosis
myringotomy alone
P = 0.004Tympanosclerosis
35/61 (57%) with tympanostomy
tube
44 children, aged
9 months to 7
years with bilateral
recurrent AOM of
equal severity in
[28]
RCT
5/26 (19%) with myringotomy
aloneeach ear despite
>3 months of antibi-
otic prophylaxis
no surgery
P less than or equal to 0.0001Tympanosclerosis
35/61 (57%) with tympanostomy
tube
44 children, aged
9 months to 7
years with bilateral
recurrent AOM of
equal severity in
[28]
RCT
2/27 (7%) with no surgery
each ear despite
>3 months of antibi-
otic prophylaxis
-
No data from the following reference on this outcome. [27]
-
Symptoms of AOM
-
-
No data from the following reference on this outcome. [27] [28]
-
Adverse effects
-
-
No data from the following reference on this outcome. [27] [28]
-
-
-
Further information on studies
[27] The review included only studies that randomised children and excluded the RCT that randomised ears. [28]
[28] Recurrent AOM was defined as the recurrent presence (>4 episodes) of ear ache with red and bulging tympanic
membranes. Anatomical abnormalities (tympanosclerosis, atrophy, or retraction and chronic perforation), although
not thought to be clinically significant, were more common in the ears receiving tympanostomy tubes. The RCT
included some children with otitis media with effusion, although the results concerning benefits presented here
refer only to those children in the study with recurrent AOM. It was not possible from the data available to differ-
entiate the evidence on harms into children with recurrent AOM compared with otitis media with effusion.
Medical treatment and antibiotic prophylaxis were allowed "whenever indicated". It was not possible from the
data presented to tell whether the different groups differed in the amount of medical treatment and prophylactic
antibiotics.
-
-
Comment: None.
OPTION INFLUENZA VACCINE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . New
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Influenza vaccination in healthy children has no effect on the incidence of AOM.
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Benefits and harms
Influenza vaccine versus placebo:
We found one systematic review (search date 2007, 6 RCTs). [29]
-
Recurrence
Compared with placebo Influenza vaccine seems no more effective at preventing incidence of AOM in children aged
6 months to 7 years (moderate-quality evidence).
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Recurrence
Not significant
RR 1.00
95% CI 0.79 to 1.26
Incidence of AOM , 3 to 8
months
1249/3223 (39%) with influenza
vaccination
5253 children aged
6 months to 7
years
6 RCTs in this
analysis
[29]
Systematic
review P = 0.99
832/2030 (41%) with placebo
-
Symptoms of AOM
-
-
No data from the following reference on this outcome. [29]
-
Complications
-
-
No data from the following reference on this outcome. [29]
-
Adverse effects
-
-
No data from the following reference on this outcome. [29]
-
-
-
Further information on studies
-
-
Comment: The RCTs in the systematic review [29]  included only healthy children; therefore, we can draw no
firm conclusions about children with recurrent AOM.
OPTION XYLITOL SYRUP OR GUM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . New
• For GRADE evaluation of interventions for AOM in children, see table, p 29 .
• Xylitol must be given as prophylaxis, not as treatment.
• Xylitol chewing gum or syrup given 5 times daily has a small preventive effect on recurrence of AOM, but the
compliance issues in giving a medicine to such young children 5 times daily render it an unrealistic treatment
option.
• Xylitol is not effective when given 3 times daily or only during an acute respiratory tract infection.
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Benefits and harms
Xylitol versus placebo:
We found no systematic review, but found 4 RCTs. [30] [31] [32] [33]
-
Recurrence
Compared with placebo Xylitol given 5 times daily, but not 3 times daily, may be more effective at reducing recurrence
of AOM in children aged up to 7 years. Xylitol may be no more effective at reducing AOM recurrence when given
only during an acute respiratory tract infection (low-quality evidence). Note The issues of compliance in giving a
medicine to such young children 5 times daily render xylitol an unrealistic treatment option.
Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Recurrence of AOM
xylitol chewing
gum
ARR 8.7%
95% CI 0.4% to 17.0%
Children with at least one
episode of AOM , 2 months
19/157 (12%) with xylitol
306 children with
recurrent AOM,
mean age 5 years
[30]
RCT
P = 0.04
31/149 (21%) with control (su-
crose)
Treatment or control given 5
times daily as a chewing gum
xylitol syrup
Difference 1.02
95% CI 0.29 to 1.75
Incidence rate of AOM per per-
son-years at risk , 3 months
2.01 with xylitol syrup
857 children with
recurrent AOM
The remaining
arms assessed
[31]
RCT
5-armed
trial
P = 0.006
3.03 with control syrup
xylitol chewing
gum, control chew- 324 children in this analysis,
mean age 2.2 yearsing gum, and xylitol
lozenge
Treatment and control given 5
times daily as a syrup
xylitol chewing
gum
Difference 0.65
95% CI 0.14 to 1.16
Incidence rate of AOM per per-
son-years at risk , 3 months
1.04 with xylitol chewing gum
857 children with
recurrent AOM
The remaining
arms assessed
[31]
RCT
5-armed
trial
P  = 0.012
1.69 with control chewing gum
xylitol syrup, con-
trol syrup, and xyli-
tol lozenge
357 children in this analysis,
mean age 4.6 years
Treatment and control given 5
times daily as a chewing gum
Not significant
ARR –0.1
95% CI –8.3 to +5.8
Children with AOM , 3 weeks
34/166 (20.5%) with xylitol syrup
1277 children with
recurrent AOM
during an acute
respiratory tract in-
fection
[32]
RCT
5-armed
trial
P = 0.7232/157 (20.4%) with control syrup
323 children in this analysis,
mean age 3.6 yearsThe remaining
arms assessed
Treatment or control given 5
times daily as a syrup, only dur-
xylitol chewing
gum, control chew-
ing the acute respiratory tract in-
fection
ing gum, and xylitol
lozenges
Not significant
ARR –0.1
95% CI –9.4 to +3.2
Children with AOM , 3 weeks
31/220 (14%) with xylitol chewing
gum
1277 children with
recurrent AOM
during an acute
respiratory tract in-
fection
[32]
RCT
5-armed
trial
P = 0.33
24/218 (11%) with control chew-
ing gumThe remaining
arms assessed 438 children in this analysis,
mean age 4.8 yearsxylitol syrup, con-
trol syrup, and xyli-
tol lozenges Treatment or control given 5
times daily as a chewing gum,
only during the acute respiratory
tract infection
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Favours
Effect
size
Results and statistical
analysisOutcome, InterventionsPopulation
Ref
(type)
Not significant
Difference –0.26
95% CI –0.71 to +0.19
Incidence rate of AOM per per-
son-years at risk , 3 months
2.09 with xylitol
663 children with
recurrent AOM,
mean age 4.1
years
[33]
RCT
P = 0.25
1.83 with control
Treatment and control given 3
times daily as either a chewing
gum or syrup, depending on
whether the child was old enough
to chew gum
-
Symptoms of AOM
-
-
No data from the following reference on this outcome. [30] [31] [32] [33]
-
Complications
-
-
No data from the following reference on this outcome. [30] [31] [32] [33]
-
Adverse effects
-
-
No data from the following reference on this outcome. [30] [31] [32] [33]
-
-
-
Further information on studies
-
-
Comment: Compliance is a potential problem with a medication that must be given 5 times a day to a young
child. In addition, the preventing effect of xylitol is quite small — only one episode of AOM per year.
For the time being, then, xylitol does not represent a realistic treatment option for AOM in children.
GLOSSARY
High-quality evidence Further research is very unlikely to change our confidence in the estimate of effect.
Low-quality evidence Further research is very likely to have an important impact on our confidence in the estimate
of effect and is likely to change the estimate.
Mastoiditis The presence of infection in the mastoid cavity.
Moderate-quality evidence Further research is likely to have an important impact on our confidence in the estimate
of effect and may change the estimate.
Myringotomy The surgical creation of a perforation in the tympanic membrane.
Very low-quality evidence Any estimate of effect is very uncertain.
SUBSTANTIVE CHANGES
Influenza vaccine New option added. Categorised as Unlikely to be beneficial.
Xylitol syrup or gum New option added. Categorised as Unlikely to be beneficial.
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Analgesics for AOM in children One Cochrane systematic review updated. [10]  Categorisation unchanged (Likely
to be beneficial).
Antibiotic prophylaxis for preventing recurrence of AOM in children One Cochrane systematic review updated.
[25]
 Categorisation unchanged (Trade-off between benefits and harms).
Antibiotics versus placebo for AOM in children New evidence added. [13] [14]  Categorisation unchanged (Trade-
off between benefits and harms).
Choice of antibiotic regimen New evidence added. [18]  Categorisation unchanged (Trade-off between benefits and
harms).
Immediate or delayed antibiotics for AOM in children New evidence added. [19]  Categorisation unchanged (Trade-
off between benefits and harms).
Longer versus shorter courses of antibiotics One Cochrane systematic review updated. [21]  Categorisation un-
changed (Trade-off between benefits and harms).
Tympanostomy (ventilation tubes) New evidence added. [27]  Categorisation unchanged (Likely to be ineffective
or harmful).
Pneumococcal vaccine New evidence added. [26]  Categorisation changed from Unlikely to be beneficial to Likely
to be beneficial.
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GRADE Evaluation of interventions for AOM in children.
-
Complications, Recurrence, Symptoms of AOMImportant outcomes
CommentGRADE
Effect
size
Direct-
ness
Consisten-
cyQuality
Type of
evidenceComparisonOutcome
Studies (Partici-
pants)
What are the effects of treatments for AOM in children?
Quality point deducted for sparse data. Directness
point deducted for inclusion of studies that includ-
ed oral analgesics
Low0
–10–14Topical anaesthetic versus
placebo
Symptoms of AOM2 (117) [10]
Quality point deducted for incomplete reporting
of results. Directness point deducted for uncertain
validity of outcome assessment
Low0
–10–14Oral analgesics versus
placebo
Symptoms of AOM1 (219) [11]
Consistency point deducted for conflicting results.
Directness point deducted for range of interven-
tions included
Low0
–1–104Antibiotics versus placeboSymptoms of AOMat least 19 (at least
3805) [12] [13] [15]
High00004Antibiotics versus placeboRecurrence6 (2153) [13]
Directness point deducted for range of interven-
tions included
Moderate0
–1004Antibiotics versus placeboComplications1 (2287) [13] [14]
Quality points deducted for incomplete reporting
of results and heterogeneity of outcome measures
Very low0
–20–24Different antibiotics versus
each other
Symptoms of AOMat least 27 (at least
4580) [17] [2] [18]
and controls. Directness points deducted for
range of participants and interventions included
Consistency point deducted for conflicting resultsModerate00–104Immediate versus delayed
antibiotic treatment
Symptoms of AOM2 (498) [19]
High00004Longer versus shorter course
of antibiotics
Symptoms of AOM27 (6727) [21]
Quality points deducted for sparse data and in-
complete reporting of results
Low000–24Myringotomy versus no
myringotomy
Symptoms of AOM1 (171) [22]
Quality point deducted for incomplete reporting
of results. Consistency point deducted for conflict-
ing results
Low00–1–14Myringotomy versus antibi-
otics
Symptoms of AOM3 (821) [23] [22] [24]
What are the effects of interventions to prevent recurrence of AOM in children?
High00004Antibiotic prophylaxis versus
placebo
Recurrence13 (at least 1358) [25]
Quality points deducted for incomplete reporting
and for no intention-to-treat analyses in many
Very low00–1–24Pneumococcal vaccine ver-
sus placebo or control
Recurrence12 (46,457) [26]
RCTs. Consistency point deducted for conflicting
results
Quality points deducted for sparse data and in-
complete reporting of results. Consistency point
Very low00–1–24Tympanostomy versus no
surgery or myringotomy alone
Recurrence3 (192) [27] [28]
deducted for different results at different end
points
Quality point deducted for sparse data. Consis-
tency point deducted for different results at differ-
ent end points
Low00–1–14Tympanostomy versus no
surgery or myringotomy alone
Complications1 (44) [28]
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Complications, Recurrence, Symptoms of AOMImportant outcomes
CommentGRADE
Effect
size
Direct-
ness
Consisten-
cyQuality
Type of
evidenceComparisonOutcome
Studies (Partici-
pants)
Quality point deducted for poor methodology
(vaccination completed after the beginning of viral
circulation in 1 large RCT)
Moderate000–14Influenza vaccine versus
placebo
Recurrence6 (5253) [29]
Consistency point deducted for conflicting results.
Directness point deducted for range of interven-
tions
Low0
–1–104Xylitol versus placeboRecurrence4 (2411) [30] [31] [32][33]
We initially allocate 4 points to evidence from RCTs, and 2 points to evidence from observational studies. To attain the final GRADE score for a given comparison, points are deducted or added from this initial
score based on preset criteria relating to the categories of quality, directness, consistency, and effect size. Quality: based on issues affecting methodological rigour (e.g., incomplete reporting of results, quasi-
randomisation, sparse data [<200 people in the analysis]). Consistency: based on similarity of results across studies. Directness: based on generalisability of population or outcomes. Effect size: based on magnitude
of effect as measured by statistics such as relative risk, odds ratio, or hazard ratio.
-
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